MILNE JILL C.,JIROUSEK MICHAEL R.,BEMIS JEAN E.,SMITH JESSE J.
申请号：
NZ60193209
公开号：
NZ601932A
申请日:
2009.07.08
申请国别(地区):
NZ
年份:
2014
代理人:
摘要：
Disclosed is a molecular conjugate comprising a salicylate and a fatty acid wherein the fatty acid is selected from the group consisting of omega-3 fatty acids and fatty acids that are metabolized in vivo to omega-3 fatty acids, wherein the conjugate: is stable to oral dosing； is stable in plasma； and is capable of enzymatic hydrolysis to produce free salicylate and free fatty acid； wherein the conjugate after hydrolysis blunts pro-inflammatory activity and activates anti-inflammatory activity. The fatty acid is selected from the group consisting of all cis-7, 10, 13-hexadecatrienoic acid, a-linolenic acid, stearidonic acid, eicosatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid (EPA), docosapentaenoic acid, docosahexaenoic acid (DHA), tetracosapentaenoic acid, and tetracosahexaenoic acid. The salicylate is selected from salicylic acid, substituted salicylate, aminosalicylic acid, diflunisal and triflusal.
